Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

Pascale Massin; Francesco Bandello; Justus G Garweg; Lutz L Hansen; Simon P Harding; Michael Larsen; Paul Mitchell; Dianne Sharp; U E K Wolf-Schnurrbusch; Margarita Gekkieva; Andreas Weichselberger; Sebastian Wolf

doi:10.2337/dc10-0493

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

Pascale Massin, Francesco Bandello, Justus G Garweg, Lutz L Hansen, Simon P Harding, Michael Larsen, Paul Mitchell, Dianne Sharp, U E K Wolf-Schnurrbusch, Margarita Gekkieva, Andreas Weichselberger, Sebastian Wolf

Department of Ophthalmology

683 Citations (Scopus)

Abstract

The expression of vascular endothelial growth factor (VEGF) is elevated in diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants. We investigated the safety and efficacy of ranibizumab in DME involving the foveal center.

Original language	English
Journal	Diabetes Care
Volume	33
Issue number	11
Pages (from-to)	2399-405
Number of pages	7
ISSN	0149-5992
DOIs	https://doi.org/10.2337/dc10-0493
Publication status	Published - 1 Nov 2010

Access to Document

10.2337/dc10-0493

Cite this

Massin, P., Bandello, F., Garweg, J. G., Hansen, L. L., Harding, S. P., Larsen, M., Mitchell, P., Sharp, D., Wolf-Schnurrbusch, U. E. K., Gekkieva, M., Weichselberger, A., & Wolf, S. (2010). Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care, 33(11), 2399-405. https://doi.org/10.2337/dc10-0493

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. / Massin, Pascale; Bandello, Francesco; Garweg, Justus G et al.
In: Diabetes Care, Vol. 33, No. 11, 01.11.2010, p. 2399-405.

Research output: Contribution to journal › Journal article › Research › peer-review

Massin, P, Bandello, F, Garweg, JG, Hansen, LL, Harding, SP, Larsen, M, Mitchell, P, Sharp, D, Wolf-Schnurrbusch, UEK, Gekkieva, M, Weichselberger, A & Wolf, S 2010, 'Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study', Diabetes Care, vol. 33, no. 11, pp. 2399-405. https://doi.org/10.2337/dc10-0493

@article{e71f8f14365f48818d32b6ad00208e87,

title = "Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study",

abstract = "The expression of vascular endothelial growth factor (VEGF) is elevated in diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants. We investigated the safety and efficacy of ranibizumab in DME involving the foveal center.",

author = "Pascale Massin and Francesco Bandello and Garweg, \{Justus G\} and Hansen, \{Lutz L\} and Harding, \{Simon P\} and Michael Larsen and Paul Mitchell and Dianne Sharp and Wolf-Schnurrbusch, \{U E K\} and Margarita Gekkieva and Andreas Weichselberger and Sebastian Wolf",

year = "2010",

month = nov,

day = "1",

doi = "10.2337/dc10-0493",

language = "English",

volume = "33",

pages = "2399--405",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "American Diabetes Association",

number = "11",

}

TY - JOUR

T1 - Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

AU - Massin, Pascale

AU - Bandello, Francesco

AU - Garweg, Justus G

AU - Hansen, Lutz L

AU - Harding, Simon P

AU - Larsen, Michael

AU - Mitchell, Paul

AU - Sharp, Dianne

AU - Wolf-Schnurrbusch, U E K

AU - Gekkieva, Margarita

AU - Weichselberger, Andreas

AU - Wolf, Sebastian

PY - 2010/11/1

Y1 - 2010/11/1

N2 - The expression of vascular endothelial growth factor (VEGF) is elevated in diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants. We investigated the safety and efficacy of ranibizumab in DME involving the foveal center.

AB - The expression of vascular endothelial growth factor (VEGF) is elevated in diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants. We investigated the safety and efficacy of ranibizumab in DME involving the foveal center.

UR - https://www.scopus.com/pages/publications/79251606719

U2 - 10.2337/dc10-0493

DO - 10.2337/dc10-0493

M3 - Journal article

C2 - 20980427

SN - 0149-5992

VL - 33

SP - 2399

EP - 2405

JO - Diabetes Care

JF - Diabetes Care

IS - 11

ER -

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

Abstract

Access to Document

Other files and links

Fingerprint

Cite this